Next Generation Sequencer

下一代测序仪

• 批准号: 7791131
• 负责人: Charis Eng
• 金额: $ 50万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-11 至 2011-03-10
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7791131
• 关键词: Applications Grants; Biological Markers; Clinic; Clinical; Commit; Core Facility; DNA; DNA-Protein Interaction; Detection; Development; Ensure; Epigenetic Process; Functional RNA; Funding; Gene Expression Profiling; Generations; Genome; Genomics; Human Resources; Institute of Medicine (U.S.); Institution; Lifting; Maintenance; Marketing; Medicine; Ohio; Patients; Regulation; Research; Research Project Grants; Resources; Running; Technology; Transcript; Translational Research; United States National Institutes of Health; Work; base; digital; disease-causing mutation; flexibility; genome sequencing; genome-wide; human disease; instrument; instrumentation; next generation; operation; programs

DESCRIPTION (provided by applicant): The proposed work in this shared instrumentation grant application comes from many of the clinical and/or translational research programs ongoing at the Cleveland Clinic, a major research institution in the northeast Ohio region. The purpose of this application is to seek funding to purchase a next generation sequencer, the Illumina Genome Analyzer IIx. All but one of the major users is NIH/NCI funded by a variety of mechanisms (R01, P01, U54, etc). The Genome Analyzer has the power and flexibility to enable a wide range of genome-scale applications. The instrument is a direct consequence of the NIH initiative for the $1000 genome and represents the first generation of such technologies to come to the market. The underlying technology can be summarized as massive parallel sequencing (creating 2-4 GB of sequence in a typical 3-5 day run). As detailed in the application, the supported projects primarily include biomarker discovery and clinical/translational sciences studies, representing the unique strengths in our institution and taking advantage of all current applications of the next generation sequencers: 1) digital gene expression profiling: better dynamic range than micro-array based profiling and reliable detection of low-abundance transcripts, 2) ChIP-seq: genome wide profiles of DNA-protein interaction and of epigenetic regulation in translational research programs related to human disease, 3) small or non-coding RNA discovery and 4) genome sequencing: re- sequencing of large genomic regions in patient DNA to uncover disease causing mutations. The acquisition of the Genome Analyzer, with its scale and value, are essential in lifting the currently NIH-funded projects and many other new projects to the next higher level of translational sciences in northeast Ohio. Cleveland Clinic has already committed substantial resources to the development of translational genomics and genomic medicine, including the founding of its Genomic Medicine Institute with a new Genomics Core Facility, personnel to oversee operations and a fiscal plan to ensure its operation and maintenance for the long-term.

描述（由申请人提供）：此共享工具赠款申请中的拟议工作来自克利夫兰诊所的许多临床和/或转化研究计划，克利夫兰诊所是俄亥俄州东北部的主要研究机构。该应用程序的目的是寻求资金购买下一代测序仪Illumina Genome Analyzer IIX。除了主要用户外，所有其他用户中的所有人都是NIH/NCI，由多种机制（R01，P01，U54等）资助。基因组分析仪具有实现广泛基因组规模应用的能力和灵活性。该仪器是NIH倡议的直接结果，该计划是1000美元的基因组，代表了进入市场的第一代技术。基础技术可以总结为大量并行测序（在典型的3-5天运行中创建2-4 GB的序列）。 As detailed in the application, the supported projects primarily include biomarker discovery and clinical/translational sciences studies, representing the unique strengths in our institution and taking advantage of all current applications of the next generation sequencers: 1) digital gene expression profiling: better dynamic range than micro-array based profiling and reliable detection of low-abundance transcripts, 2) ChIP-seq: genome wide profiles of DNA-protein interaction and of与人类疾病有关的转化研究计划中的表观遗传调节，3）小或非编码的RNA发现和4）基因组测序：对患者DNA中大基因组区域的重新测序，以发现引起突变的疾病。及其规模和价值的基因组分析仪的获取对于将当前的NIH资助项目和许多其他新项目提升到俄亥俄州东北部的下一个更高水平的转化科学至关重要。克利夫兰诊所已经为开发转化基因组学和基因组医学的发展提供了大量资源，包括建立其基因组医学研究所，具有新的基因组学核心设施，负责监督运营的人员以及一项财政计划，以确保其长期运作和维护。